Completed PHASE2 INTERVENTIONAL 2-arm NCT00818441

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG

Sponsor: Pfizer

Updated 9 times since 2017 Last updated: Dec 19, 2018 Started: Mar 11, 2009 Primary completion: Apr 27, 2012 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00818441, this PHASE2 trial focuses on Carcinoma, Non-small Cell and remains completed. Sponsored by Pfizer, it has been updated 9 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Feb 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Feb 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Aurora, United States , Bethesda, United States , Bismarck, United States , Boston, United States , Chapel Hill, United States , Chattanooga, United States , Durham, United States , Fort Myers, United States , Koto-Ku, Japan and 15 more locations